Biohaven Completes Enrollment in Pivotal Epilepsy Study, Results Expected H2 2026
BHVN sits 96% above its 52-week low of $7.48.
Summary
Biohaven has completed enrollment for its pivotal Phase 2/3 RISE3 study of Opakalim for focal epilepsy. This is a critical step in the drug's development, following positive clinical data reported for Opakalim in late May. The completion of enrollment de-risks the study timeline and sets the stage for the next major catalyst. Top-line results from the RISE3 study are anticipated in the second half of 2026.
At the time of this announcement, BHVN was trading at $14.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.